How to appeal a CareFirst BCBS ms treatments denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

CareFirst BCBS-specific note: BCBS licensee for Maryland, DC, and northern Virginia (~3.5M members). Operates as non-profit. Appeals jurisdiction depends on policy issue location — MIA (MD), DISB (DC), or SCC Bureau of Insurance (VA). CVS Caremark is the PBM.

What CareFirst BCBS's policy requires for ms treatments

Cited policy: Anthem BCBS Clinical UM Guideline clinical guideline - Ocrelizumab (Ocrevus); plan-specific MS DMT policies

Confirmed MS diagnosis with subtype. Step therapy through preferred DMTs (varies by BCBS affiliate). Recent MRI within 6-12 months for new starts of high-efficacy. Specialty pharmacy distribution. HSCT for MS generally classified as investigational.

How CareFirst BCBS denies ms treatments — and how to counter it

Where CareFirst BCBS pushes back: 1) Step therapy not met — typically 2 platforms or 1 oral required; 2) Plan considers HSCT for MS investigational; 3) Briumvi denied — Ocrevus is preferred anti-CD20; 4) Inadequate documentation of breakthrough on prior DMT.

Counter-arguments that hold up: AAN 2018 (reaffirmed 2022) + ECTRIMS/EAN 2018 supporting early high-efficacy in highly active MS without mandatory platform trials. OPERA I/II, ASCLEPIOS I/II, ULTIMATE I/II all show high-efficacy anti-CD20 superiority. For HSCT: MIST trial (JAMA 2019) showed superiority to best DMT with sustained disability improvement; EBMT 2020 lists HSCT as standard for treatment-refractory highly active RRMS. Within-class Briumvi denial: ULTIMATE I/II + lower IV time burden + patient-specific factors.

What CareFirst BCBS typically denies for ms treatments

Across CareFirst BCBS's commercial and Medicare books, denials cluster around a small number of patterns. For ms treatments, expect:

• DC/MD/VA cross-jurisdiction issues
• Step therapy on specialty drugs via CVS Caremark
• Behavioral health network adequacy
• BlueChoice HMO referral denials

Treatments most often denied in this category

These are the ms treatments treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Ocrevus
• Kesimpta
• Briumvi
• Tysabri
• Lemtrada
• S1P modulator

How to submit the appeal to CareFirst BCBS

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document CareFirst BCBS cited in the denial.
3. File the appeal through CareFirst BCBS's portal (members: https://member.carefirst.com ; providers: https://provider.carefirst.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In MD, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See CareFirst BCBS's prior-authorization criteria by drug: CareFirst BCBS PA criteria on ApprovalHelp.